China News Service, June 13th. According to a Reuters report on the 12th, the European Medicines Agency recently listed another rare blood disease-capillary leak syndrome (CLS) as a potential vaccine for AstraZeneca's new crown vaccine. side effect.
Data map: The picture shows people entering and exiting the vaccination center in Frankfurt, Germany.
Photo by China News Agency reporter Peng Dawei
According to reports, the European Medicines Agency Safety Committee pointed out on the 11th that AstraZeneca must list such side effects on the label.
The committee also recommends that people who have previously experienced swelling and blood pressure drop due to CLS should not receive the AstraZeneca vaccine.
The European Medicines Agency began investigating these cases in April.
The committee reviewed six cases of CLS. Most of the patients were women. They were vaccinated with AstraZeneca. One of the vaccinators died; the other three had a history of CLS.
The report pointed out that the latest recommendations of the European Medicines Agency put AstraZeneca into a deeper predicament.
Previously, many countries had reported cases of death from blood clots after inoculation with AstraZeneca vaccine, which once caused concern.
On April 7, the European Medicines Agency announced that thrombosis with low platelets should be listed as a rare side effect of the AstraZeneca vaccine.
Some European countries also require the vaccine to be used with caution in some populations.
According to Reuters, as of now, more than 78 million doses of AstraZeneca vaccine have been injected in European Union countries, Iceland, Norway and the United Kingdom.